Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: a prospective study with the LiMAx test
| Autor: | Johan F. Lock, Peter Neuhaus, Magnus Kaffarnik, Navid Ahmadi, Maciej Malinowski, Christian Lojewski, Hannah Vetter, Martin Stockmann |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Indocyanine Green Male medicine.medical_specialty Resuscitation Population Critical Care and Intensive Care Medicine Gastroenterology Sepsis Liver Function Tests Renal Dialysis Risk Factors Internal medicine Medicine Humans Prospective Studies education Coloring Agents APACHE Aged LiMAx test Aged 80 and over education.field_of_study Limax biology medicine.diagnostic_test business.industry Septic shock Research Liver Diseases Length of Stay Middle Aged medicine.disease biology.organism_classification Prognosis Respiration Artificial eye diseases Surgery Transplantation Early Diagnosis Female Liver function business Liver function tests |
| Zdroj: | Critical Care |
| ISSN: | 1466-609X 1364-8535 |
| Popis: | Introduction Liver dysfunction can derive from severe sepsis and might be associated with poor prognosis. However, diagnosis of septic liver dysfunction is challenging due to a lack of appropriate tests. Measurement of maximal liver function capacity (LiMAx test) has been successfully evaluated as a new diagnostic test in liver resection and transplantation. The aim of this study was to evaluate the LiMAx test during sepsis in comparison to biochemical tests and the indocyanin green test (ICG-PDR). Methods We prospectively investigated 28 patients (8 female and 20 male, age range 35 to 80 years) suffering from sepsis on a surgical ICU. All patients received routine resuscitation from septic shock (surgery, fluids, catecholamines, antibiotic drugs). The first LiMAx test and ICG-PDR were carried out within the first 24 hours after onset of septic symptoms, followed by day 2, 5 and 10. Other biochemical parameters and scores determining the severity of illness were measured daily. Clinical outcome parameters were examined after 90 days or at the end of treatment. The population was divided into 2 groups (group A: non-survivors or ICU length of stay (ICU-LOS) >30 days versus group B: survivors and ICU-LOS |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink